Spain-based biotech venture capital firm, Ysios Capital, has closed its third fund, Ysios BioFund 3 (YBF 3) at €216m (US$264m). Its largest fund to date, YBF 3 will invest across multiple therapeutic areas, targeting seed/early stage and development-stage companies. Total investment per company will typically be up to €20m for lead positions. As with previous…
Home Healthcare Markets International News Spain: Ysios Capital targets 15 investments from close of €216m third fund